U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H14N2O3
Molecular Weight 282.294
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENDAZAC

SMILES

OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3

InChI

InChIKey=BYFMCKSPFYVMOU-UHFFFAOYSA-N
InChI=1S/C16H14N2O3/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,20)

HIDE SMILES / InChI

Molecular Formula C16H14N2O3
Molecular Weight 282.294
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Bendazac, (1-benzyl-1H-indazol-3-yl-oxy)-acetic acid, is structurally related to indomethacin. Its lysine salt has been reported to be absorbed better than the parent compound. It is applied topically as bendazac lysine 0.5% (wt/vol) aqueous solution for delaying the progression of cataract. Topical application of bendazac is associated with transient burning sensation. It reduces the secretion of the skin ulcer surface, promotes skin formation and accelerates tissue repair.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.33 mM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zildasac Ointment
Primary
Zildasac Ointment
Primary
Zildasac Ointment
Primary
Zildasac Ointment
Palliative
Zildasac Ointment
Primary
BENDAZAC LYSINE

PubMed

Sample Use Guides

In Vivo Use Guide
Single Dose Eye drops: 2 drops in each eye or half the contents of a single-dose, three times a day Multi-dose eye drops: 2 drops in each eye, three times a day oral: single dosage benzadac lysine in tables (500 mg) Skin ulcers: An appropriate amount of this product is applied to the affected area several times a day. Incidentally, it performs patch therapy 1-2 times daily as needed. Inflammatory skin disease: An appropriate amount of this product is applied to the affected area several times a day.
Route of Administration: Other
In Vitro Use Guide
The inhibition of labelled cyanate binding to lens proteins increased with increasing concentration of bendazac (max at 40 mM).
Substance Class Chemical
Record UNII
G4AG71204O
Record Status Validated (UNII)
Record Version